In a report issued on February 20, Ahu Demir from Noble Financial maintained a Buy rating on Dyadic International (DYAI), with a price target of $4. The company’s shares closed on Friday at $2.85, close to its 52-week high of $2.91.
Demir has an average return of 47.6% when recommending Dyadic International.
According to TipRanks.com, Demir is ranked #3224 out of 5205 analysts.
Dyadic International has an analyst consensus of Moderate Buy, with a price target consensus of $4.
See today’s analyst top recommended stocks >>
Based on Dyadic International’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $1.54 million. In comparison, last year the company had a GAAP net loss of $1.37 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dyadic International, Inc. operates as a biotechnology company. It uses its patented and proprietary technologies for the discovery, development, manufacture, and sale of enzymes and other proteins for the bioenergy, biochemical, biopharmaceutical, and industrial enzyme industries.